- Email: [email protected]
5550022 Method for the determination of pathogenic listeria bacteria
PATENT ABSTRACTS
disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of ~msplanted cells for the ueatmont of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegnnerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.
5550020 METHOD, REAGENTS AND KIT FOR DIAGNOSIS AND TARGETED SCREENING FOR RETINOBLASTOMA Gallic Brenda L; Dunn James M; Stevens John K Toronto, CANADA Assigned to Visible Genetics Inc; HSC Research & Development Reliable and cost effective testing for mutations in the RBI gene can be accomplished by quantitatively amplifying exons of the sample RB 1 gene using primers complementary to intron regions flanking each exon; and then determining the lengths and/or quantities of the amplification products for each exon and comparing that length or quantity to the length or quantity of amplification products obtained when a wild-typo RB1 gene is amplified using the same primers. Differences in length between an amplified sample exon and the corresponding amplified wild-type exon reflect the occurrence of an insertion or deletion mutation in the sample RB 1 gene. Differences in quantity reflect the complete absence of an exon, or heterozygosity for a mutant exon. Next, the nucleic acid sequence of each exon found to contain an insertion or deletion mutation is deamnined, or of all exons in the event no insextion or deletion mutations are
421
identified, Preferably, the amplification of the exons is multiplexed so that more than one exon is amplified in a single vessel using sets of primers which provide gene froonents of distinctive lengths when used to amplify a normal RB 1 gene.
5550021 ALLELIC DIAGNOSIS OF SUSCEPTIBILITY TO COMPULSIVE DISORDER Bhim Kenneth; Noble Ernest P; Sheridan Peter J San Antonio, TX, UNITED STATES Assigned to Board of Regents The University of Texas System; Regents of the University of California In an important embodiment, the present invention concerns a method for diagnosing and detecting compulsive disorder susceptibility of an individual. The method comprises initially obtaining a DNA sample of said individual and then determining the presence or absence of particular human D2 receptor gene alleles in said sample. Detection of said alleles in the sample are indicative of predilection to compulsive disorder. A most preferred embodiment is to detect predisposition to impulsive, addictive, and compulsive disorders such as, but not limited to, alcoholism, obesity, smoking, polysubstnnce abuse and drug addictioa,paRicula~ because said alleles have been found to be inesent in a majority of individuals clinically diagnosed with these compulsive disorders. The human D2 receptor gone AI, B1, and In6-Ex7 haplotype I alleles are most preferably detected in said sample.
5550022 METHOD FOR THE DETERMINATION OF PATHOGENIC LISTERIA BACTERIA Chakraborty Trinad; Goebel Werner; Notermans Servatins H W Worzburg, GERMANY Assigned to Boehringer Mannheim GmbH Nucleic acids which preferably hybridize under the hybridization conditions 5-6* SSC and 42°C to 60°C with a 2.5 kb large Kpnl-BamHI
422
PATENT ABSTRACTS
fragment from pLM63, preferably with a nucleic acid. Such nucleic acids are suitable for hybridization tests for Listeria bacteria if they contain reporter groups. Proteins are also described which are suitable for the production of antibodies against Listeria bacteria.
5550029 M E T H O D FOR DIAGNOSING E S T R O G E N RESPONSIVENESS Simpkins James W; Bishop Jean Gainesville, FL, UNITED STATES Assigned to University of Florida
5550024 GENETIC M A R K E R S F O R PIG LITTER SIZE Rothschild Max; Tuggle Christopher K; Jacobson Carol; Vaske David A; Mileham Alan J; Plastow Graham Ames, IA, UNITED STATES Assigned to Bioteehnology Research & Development Corporation; Iowa State University Research Foundation Inc Disclosed herein are genetic markers for pig litter size, methods for identifying such markers, and methods of screening pigs to determine those more likely to produce larger fitters and preferably selecting those pigs for future breeding purposes based on the ESR polymorphisms. The markers are based upon the presence or absence of certain polymorphisms in the pig estrogen receptor gene. Preferably, the polymorphism is a restriction fragment length polymorphism (RFLP).
5550028 T E T R A H Y D R O X Y Q U I N O N E AS AN A C T I V A T O R C O M P O N E N T FOR A C T I V A T E D PARTIAL T H R O M B O P L A S T I N TIME TEST OF B L O O D COAGULATION Lee Ted C; Pelzer Franz; Motley Leslie A Plantation, FL, UNITED STATES Assigned to Dade International lnc The compound 2,3,5,6-tetrahydroxy- 1,4-quinone, its derivatives and structural analogs are used as activators for intrinsic blood coagulationand as diagnostic reagents for the activated partial thromboplastin time test of blood coagulation.
A method and diagnostic kit is provided for diagnosing responsiveness to a hormone in a human subject that includes determining the amount of glucose utilized by a sample taken from the subject in the presence of the hormone. The sample taken from the subject may include body fluid or body tissue such as blood or skin. The glucose ufflized in the test may be labelled for example, with a radioactive label. The diagnostic test may be used to determine responsiveness to estrogen in a human subject prior to treatment with hormone replacement therapy.
5550030 REAGENT FOR ENDOTOXIN-SPECIFIC ASSAY Tanaka Shigenori; Tamura Hiroshi; Ohki Makoto Tokyo, JAPAN Assigned to Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Disclosed are a reagent for endotoxin-spocific assay which comprises an insoluble carrier having immobilized thereon at least an endotoxin-sansitive factor derived from a limulus amebocyte; a kit for endotoxin-specific assay containing said reagent and a substrate for activated factor C or a substrate for clotting enzyme; a method for assaying endotoxin comprising applying a sample solution to said reagent to cause endotoxin in the sample to react with factor C in said reagent and determining a change of a subswate; and a process for preparing said reagent which comprises physically or chemically immobilizing at least an endotoxin-sensitive factor derived from a fimuhis amebocyte on an insoluble carrier. Endotoxin in a sample, even turbid or colored, can be specifically assayed with ease and rapidness without the influence of a (1 right arrow3)beta-glucan.
disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of ~msplanted cells for the ueatmont of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegnnerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.
5550020 METHOD, REAGENTS AND KIT FOR DIAGNOSIS AND TARGETED SCREENING FOR RETINOBLASTOMA Gallic Brenda L; Dunn James M; Stevens John K Toronto, CANADA Assigned to Visible Genetics Inc; HSC Research & Development Reliable and cost effective testing for mutations in the RBI gene can be accomplished by quantitatively amplifying exons of the sample RB 1 gene using primers complementary to intron regions flanking each exon; and then determining the lengths and/or quantities of the amplification products for each exon and comparing that length or quantity to the length or quantity of amplification products obtained when a wild-typo RB1 gene is amplified using the same primers. Differences in length between an amplified sample exon and the corresponding amplified wild-type exon reflect the occurrence of an insertion or deletion mutation in the sample RB 1 gene. Differences in quantity reflect the complete absence of an exon, or heterozygosity for a mutant exon. Next, the nucleic acid sequence of each exon found to contain an insertion or deletion mutation is deamnined, or of all exons in the event no insextion or deletion mutations are
421
identified, Preferably, the amplification of the exons is multiplexed so that more than one exon is amplified in a single vessel using sets of primers which provide gene froonents of distinctive lengths when used to amplify a normal RB 1 gene.
5550021 ALLELIC DIAGNOSIS OF SUSCEPTIBILITY TO COMPULSIVE DISORDER Bhim Kenneth; Noble Ernest P; Sheridan Peter J San Antonio, TX, UNITED STATES Assigned to Board of Regents The University of Texas System; Regents of the University of California In an important embodiment, the present invention concerns a method for diagnosing and detecting compulsive disorder susceptibility of an individual. The method comprises initially obtaining a DNA sample of said individual and then determining the presence or absence of particular human D2 receptor gene alleles in said sample. Detection of said alleles in the sample are indicative of predilection to compulsive disorder. A most preferred embodiment is to detect predisposition to impulsive, addictive, and compulsive disorders such as, but not limited to, alcoholism, obesity, smoking, polysubstnnce abuse and drug addictioa,paRicula~ because said alleles have been found to be inesent in a majority of individuals clinically diagnosed with these compulsive disorders. The human D2 receptor gone AI, B1, and In6-Ex7 haplotype I alleles are most preferably detected in said sample.
5550022 METHOD FOR THE DETERMINATION OF PATHOGENIC LISTERIA BACTERIA Chakraborty Trinad; Goebel Werner; Notermans Servatins H W Worzburg, GERMANY Assigned to Boehringer Mannheim GmbH Nucleic acids which preferably hybridize under the hybridization conditions 5-6* SSC and 42°C to 60°C with a 2.5 kb large Kpnl-BamHI
422
PATENT ABSTRACTS
fragment from pLM63, preferably with a nucleic acid. Such nucleic acids are suitable for hybridization tests for Listeria bacteria if they contain reporter groups. Proteins are also described which are suitable for the production of antibodies against Listeria bacteria.
5550029 M E T H O D FOR DIAGNOSING E S T R O G E N RESPONSIVENESS Simpkins James W; Bishop Jean Gainesville, FL, UNITED STATES Assigned to University of Florida
5550024 GENETIC M A R K E R S F O R PIG LITTER SIZE Rothschild Max; Tuggle Christopher K; Jacobson Carol; Vaske David A; Mileham Alan J; Plastow Graham Ames, IA, UNITED STATES Assigned to Bioteehnology Research & Development Corporation; Iowa State University Research Foundation Inc Disclosed herein are genetic markers for pig litter size, methods for identifying such markers, and methods of screening pigs to determine those more likely to produce larger fitters and preferably selecting those pigs for future breeding purposes based on the ESR polymorphisms. The markers are based upon the presence or absence of certain polymorphisms in the pig estrogen receptor gene. Preferably, the polymorphism is a restriction fragment length polymorphism (RFLP).
5550028 T E T R A H Y D R O X Y Q U I N O N E AS AN A C T I V A T O R C O M P O N E N T FOR A C T I V A T E D PARTIAL T H R O M B O P L A S T I N TIME TEST OF B L O O D COAGULATION Lee Ted C; Pelzer Franz; Motley Leslie A Plantation, FL, UNITED STATES Assigned to Dade International lnc The compound 2,3,5,6-tetrahydroxy- 1,4-quinone, its derivatives and structural analogs are used as activators for intrinsic blood coagulationand as diagnostic reagents for the activated partial thromboplastin time test of blood coagulation.
A method and diagnostic kit is provided for diagnosing responsiveness to a hormone in a human subject that includes determining the amount of glucose utilized by a sample taken from the subject in the presence of the hormone. The sample taken from the subject may include body fluid or body tissue such as blood or skin. The glucose ufflized in the test may be labelled for example, with a radioactive label. The diagnostic test may be used to determine responsiveness to estrogen in a human subject prior to treatment with hormone replacement therapy.
5550030 REAGENT FOR ENDOTOXIN-SPECIFIC ASSAY Tanaka Shigenori; Tamura Hiroshi; Ohki Makoto Tokyo, JAPAN Assigned to Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Disclosed are a reagent for endotoxin-spocific assay which comprises an insoluble carrier having immobilized thereon at least an endotoxin-sansitive factor derived from a limulus amebocyte; a kit for endotoxin-specific assay containing said reagent and a substrate for activated factor C or a substrate for clotting enzyme; a method for assaying endotoxin comprising applying a sample solution to said reagent to cause endotoxin in the sample to react with factor C in said reagent and determining a change of a subswate; and a process for preparing said reagent which comprises physically or chemically immobilizing at least an endotoxin-sensitive factor derived from a fimuhis amebocyte on an insoluble carrier. Endotoxin in a sample, even turbid or colored, can be specifically assayed with ease and rapidness without the influence of a (1 right arrow3)beta-glucan.